An Open-Label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs APR 246 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Aprea
- 18 Sep 2012 Results have been published in the Journal of Clinical Oncology according to an Aprea media release. Results were also summarised in the media release.
- 24 Nov 2010 Status changed from recruiting to completed, as reported in ClincialTrials.gov.
- 28 May 2010 Trial design will be discussed at the annual American Society of Clinical Oncology (ASCO) conference, as reported in an Aprea AB media release